S

Spirair

Minimally invasive ENT nasal implants

R&D Engineer - Medical Device

Full-Time
$100k - $120k
Junior, Mid
Bachelor's
South San Francisco, CA, USA
Hybrid
Biology & BiotechBiomedical Engineering & Medical Devices
No H1B Sponsorship

About the job

Requirements
  • A Bachelor's degree in Engineering or equivalent is preferred.
  • Two to five years of research and development experience are preferred.
  • Proficiency in SolidWorks for solid models and dimensioned drawings is preferred.
  • Good documentation skills are preferred.
  • Ability to multitask and prioritize with flexibility in a startup environment is preferred.
  • Proficiency in Microsoft Word, Excel, and PowerPoint is preferred.
  • Legal authorization to work in the United States is required.
Responsibilities
  • Design and implement new methodologies, materials, machines, processes, or products.
  • Develop new concepts from initial design through market release.
  • Ensure design control requirements are met, manage product development timelines, and work with a cross-functional team to commercialize new devices in a timely manner.
  • Design test and assembly fixtures in collaboration with engineering and manufacturing as appropriate.
  • Test designs to validate their intended function, including generating and reviewing test protocols, and propose design modifications to meet specific market needs.
  • Participate in animal and cadaver feasibility studies as needed throughout development to ensure desired functionality.
  • Perform verification testing to establish that new devices meet design input specifications.
  • Develop tools to accompany marketed devices when required.
  • Create detailed documentation throughout the stages and steps of research and development.
  • Work with manufacturing and production as needed to ensure product manufacturability.
  • Provide technical support for regulatory, clinical, or sales efforts when required.
  • Participate in idea generation, including brainstorming and intellectual property development.
  • Perform other duties assigned or deemed appropriate to the company or position.

About the company

Spirair develops minimally invasive ENT medical devices. Its SeptAlign system uses a bioabsorbable implant to straighten minor nasal septal deviations in an in-office procedure under local anesthesia, with the implant dissolving in about six months after the cartilage holds its new shape. In 2025 it added TurbAlign to separate the middle turbinate from the nasal wall to aid healing after sinus surgery. The company sells these devices to ENT professionals and differentiates itself by tissue-preserving implants for office-based correction, aiming to improve nasal airway outcomes with less invasive options and shorter recovery.

Company Size

11-50

Company Stage

N/A

Total Funding

N/A

Headquarters

Mountain View, California

Founded

2020

Get referred to Spirair

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Spirair secured two FDA clearances within seven months, broadening its ENT device portfolio.
  • The company updated news through August 2026, indicating active commercial and regulatory momentum.
  • Local-anesthesia office procedures attract ENTs seeking faster throughput than operating-room septoplasty.

What critics are saying

  • Cigna's 2026 policy excludes absorbable nasal implants, crushing reimbursement for Spirair sales.
  • Septoplasty remains broadly covered in 2026, keeping cheap surgical incumbents entrenched.
  • Spirair filed a 2025 exempt offering for $23.6 million, signaling continuing capital dependence.

What makes Spirair unique

  • SeptAlign won FDA clearance on January 16, 2026 for nasal septal deviation.
  • TurbAlign won FDA clearance on July 11, 2025 for post-sinus-surgery healing support.
  • Stanford Biodesign founders Brandon McCutcheon and James Kintzing built a surgeon-led ENT platform.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

20%

1 year growth

20%

2 year growth

26%
Intelligence360 News
Sep 12th, 2025
Spirair Raises $23.6M in New Funding

Spirair has filed a notice with the U.S. SEC for an exempt offering of securities to raise up to $23.6 million in new funding. This filing is required under federal securities law for companies selling securities without registration under the Securities Act of 1933, using exemptions like Rule 504 or 506 of Regulation D. The notice must be filed within 15 days of the first sale. Spirair specializes in minimally invasive solutions for ENT care.